Feasibility of screening for atrial fibrillation in a domiciliary setting: opportunistic one-time screening at preventive home visits in municipalities
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 988 KB, PDF-dokument
Current evidence base for atrial fibrillation (AF) screening is insufficient. An important finding in the STROKESTOP study was that non-participants had significantly worse outcomes. In a group of potentially non-participants feasibility of opportunistic screening in a domiciliary setting with municipality preventive home visits to citizens ≥75 years was investigated. Handheld ECG device was used by trained municipality caregivers followed by cardiologist assessment. Eighty-five percent consented to being screened, and seven of 477 screened were found with AF. Opportunistic screening in preventive home visits had a high participation rate and was feasible. Randomized trials are needed before making any firm conclusions.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Scandinavian Cardiovascular Journal |
| Vol/bind | 56 |
| Udgave nummer | 1 |
| Sider (fra-til) | 243-246 |
| Antal sider | 4 |
| ISSN | 1401-7431 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
This study was sponsored by the Alliance of BMS Denmark and Pfizer Denmark Aps. Each of the municipalities and their employees involved in the AFFORD-2 study are acknowledged for their work and participation. The municipalities and their employees did not receive any payment for their participation in the study. Andreas Habicht, Signifikans Aps., provided as a paid contractor to Pfizer Denmark Aps. database management and assisted in the statistical analysis. Mette Mortensen, Pfizer, assisted with the project management and contact to the municipality during the study.
Funding Information:
UD and LF were paid by Pfizer Denmark Aps. for their work as a member of the study steering committee. LF has been an advisory board member for BMS/Pfizer and MSD and is supported by a grant from the Health Research Foundation of Central Denmark Region. UH was a member of the study steering committee but was not paid by Pfizer Denmark Aps. for her participation and work on the study in accordance with the agreement made between Pfizer and the Municipality of Vordingborg. IML was paid by Pfizer Denmark Aps. for her specialist assessment of ECG’s and correspondence with the municipalities. TAM and HBE were both working on the study in Rebild and Horsens Municipalities, but were fully paid by each of the two municipalities and did not in accordance with the agreements between Pfizer and the two municipalities receive any payments from Pfizer. DWW was a paid contractor to Pfizer Denmark Aps. for her work as the CRO project leader role of the study and work as a member of the study steering committee. PBP and LD are full-time employees of Pfizer Denmark Aps. and were both members of the study steering committee. The authors report no other competing interests in this work.
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
ID: 321834992